In Heart Transplant Patients, Vaccination Reduces Severe COVID-19 Risk
According to a research published online April 27 in JAMA Cardiology, COVID-19 immunisation is linked to reduced COVID-19 infections, hospitalizations, and fatalities among orthotopic heart transplant (OHT) patients, with no heart transplant-specific side effects.
Laura L. Peters, D.N.P., of the University of Colorado Anschutz Medical Campus in Aurora, and colleagues evaluated the safety and efficacy of COVID-19 immunisation in adult OHT patients using data from a single U.S. heart transplant programme.
Sponsored Links:
The researchers discovered that 106 of the 436 OHT patients had COVID-19 infection. COVID-19 infections were found in 19.7% of the 366 vaccinated participants, 4.1 percent needed hospitalisation (including four ICU stays), and three patients died (0.8 percent). 48.6% of the 70 unvaccinated people were infected, 14.3% were admitted to the hospital, three needed ICU hospitalisation, and three died (4.3 percent). COVID-19 immunisation resulted in a decreased risk of all outcomes (risk ratios: infection, 0.41; hospitalization, 0.29; death, 0.19). There was no echocardiographic indication of graft malfunction, clinically severe rejection, or allosensitization six months following COVID-19 immunisation in the vaccinated OHT patients.
"Even though patients who receive a heart transplant have a lower immunogenic response to COVID-19 vaccination, the vaccine appears to be safe and is associated with a lower risk of COVID-19 infection, hospitalisation, and death, suggesting that all heart transplant recipients should get the COVID-19 vaccine," the authors write.
Comments
Post a Comment